CMND — Clearmind Medicine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1892500 ·
Last close
$3.45
Market Cap
$5.13M
52W High
$1273.60
52W Low
$3.24
ADV30
13,205
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 0 | — | -2,179,875 | -907,291 | 16,911,786 | 12,035,210 | 3,960,882 |
| Apr 2026 | 0 | — | -1,571,209 | -2,047,653 | 14,523,512 | 11,415,719 | 3,032,771 |
| Jan 2026 | 0 | — | -3,659,915 | -3,854,583 | 11,143,419 | 9,257,766 | 2,905,011 |
| Oct 2025 | 0 | — | -1,456,258 | -687,842 | 6,083,052 | 3,923,058 | 4,890,456 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,069,326
Investing CF
$-1,952,592
Financing CF
$17,569,464
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-137.28
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-34,689,251
Inventory
—
Receivables
$594,032
ST Investments
$3,894,226
EBIT TTM
$-7,477,266
Pretax Income TTM
$-7,484,674
Interest Exp TTM
$7,408
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -5,667,177 | -3,856,983 | 6,083,052 | 4,890,456 | 1,192,596 | -4,734,498 |
| Oct 2024 | 0 | -5,744,925 | -5,254,678 | 7,255,414 | 4,147,862 | 3,107,552 | -4,858,659 |
| Oct 2023 | 0 | -6,303,434 | -8,620,837 | 5,953,288 | 4,969,816 | 983,472 | -6,301,472 |
| Oct 2022 | 0 | -6,251,431 | -6,894,868 | 826,415 | 1,932,413 | -1,105,998 | -3,724,494 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PULM | Pulmatrix, Inc. | $5.00M | $1.37 | — |
| CDT | CDT Equity Inc. | $4.93M | $0.36 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $4.84M | $1.73 | — |
| BLRX | BioLineRx Ltd. | $5.43M | $1.12 | — |
| ALZN | Alzamend Neuro, Inc. | $5.45M | $1.13 | — |
News headlines (Yahoo Finance, 1h cache)
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
2026-11-16 12:37 · Yahoo
Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
2026-11-10 12:32 · Yahoo
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
2026-10-27 12:22 · Yahoo
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
2026-10-12 11:55 · Yahoo
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
2026-10-08 11:32 · Yahoo
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
2026-10-07 12:40 · Yahoo
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 13:05 · Yahoo
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 12:35 · Yahoo
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
2026-09-23 11:57 · Yahoo
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
2026-09-17 11:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.